

Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans

MINNEAPOLIS, May 21, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data highlighting the costs and outcomes of cooled high energy Transurethral Microwave Therapy (HE-TUMT), Transurethral Needle Ablation (TUNA), and the Prostatic Urethral Lift (PUL) were the topic of a podium presentation this past weekend at the American Urological Association (AUA) 2015 Annual Meeting held in New Orleans, LA.

The podium presentation titled "*Healthcare Costs for Office Based Benign Prostatic Hyperplasia Therapies*" was presented by Craig Smith, MD, FAAP, FACS, DuPage Medical Group, Chicago, IL and **co-authored by Robert G. Pugach MD, Medical Director, Pacific Coast Urology**, Huntington Beach, CA. The presentation compared the costs of HE-TUMT, TUNA and PUL to both providers and patients.

Their findings showed that, while all three treatment options show approximately 50% AUA symptom score improvement at one year, there is generally a meaningful difference in the procedure costs. Publically available data from Medicare was presented showing that payers, physicians and patients will collectively spend over \$3,100 for PUL supply costs when utilizing 4 implants per patient to treat BPH, compared to under \$1,300 for Urologix's Cooled ThermoTherapy or Prostiva procedure supply and equipment costs. This is more than twice the cost for the same general range of symptom score and flow rate improvement.

Dr. Pugach commented on the findings, "In alignment with the changes we are seeing across healthcare, these results highlight that there are two state-of-the-art, office-based solutions, Cooled ThermoTherapy and Prostiva RF Therapy, which result in excellent outcomes for patients, but provide a great comparative value as well." His co-author, Dr. Smith agreed, stating, "The current evolution of healthcare in the United States is changing the behavior of physicians, patients and payers. Costs have become more of a focus in physicians' offices due to new payment models. Higher deductibles for patients have influenced their decisions when seeking the best value in BPH therapies for their out-of-pocket expenses."

BPH is a very common disease in men over the age of 50. While not life-threatening, BPH symptoms can have a significant impact on a man's quality of life. Urologix's office-based minimally invasive therapies (MITs) are an acceptable early treatment option for men dissatisfied with BPH medications, and provide an alternative to traditional surgery for patients. Because the therapies are minimally invasive, they can be completed in the physician's office in less than an hour without the use of general anesthesia.

"In today's healthcare system, there is a growing mandate that everyone involved evaluate both the costs and the effectiveness of treatment choices," commented Greg Fluet, Chief Executive Officer of Urologix. "We are excited to provide information that will enable urologists and patients to make informed decisions and provide cost-effective treatment options for BPH patients."

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix's Cooled ThermoTherapy™ produces targeted microwave energy combined with a

unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate, destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

If you'd like more information on this topic, please contact Scott Madson at (763) 475-1400 or investor-relations@urologix.com. To learn more about Urologix and its products and services, visit their website at www.urologix.com.

The Urologix, Inc. logo is available at www.urologix.com/clinicians/resource-library.php